Shots:

• The P-III DAPA-HF study involves assessing of Farxiga (10mg) vs PBO in addition to SOC in patients with HF and reduced ejection fraction (LVEF ≤ 40%) with/out T2D
• The P-III DAPA-HF study results: 26% reduction in CV death or worsening of HF; 30% reduction in risk of experiencing a first episode of worsening HF; 18% reduction in risk of CV deaths; improvement in patients measured by KCCQ total symptom score (7.9 vs 9.5 with an event/100 patient-yrs.); patients with volume depletion (7.5% vs 6.8%); renal AEs (6.5% vs 7.2%)
• Farxiga (qd) is an oral SGLT2 inhibitor indicated both as a monothx. and combination therapy to improve glycemic control- with weight loss and reduction in BP- as an adjunct to diet and exercise in adults with T2D

Click here to­ read full press release/ article

 Ref: AstraZeneca | Image: AstraZeneca